{
    "clinical_study": {
        "@rank": "68879", 
        "acronym": "SCALP", 
        "arm_group": [
            {
                "arm_group_label": "Scalp Cooling", 
                "arm_group_type": "Experimental", 
                "description": "Scalp Cooling"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Control"
            }
        ], 
        "brief_summary": {
            "textblock": "Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in\n      reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or\n      adjuvant chemotherapy."
        }, 
        "brief_title": "Scalp Cooling to Prevent Chemo-induced Hair Loss", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Alopecia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata", 
                "Breast Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Cooling the scalp during chemotherapy may help reduce the chances of losing hair during\n      treatment.  The investigators are hoping that using the PAXMAN Orbis Scalp Cooling Device\n      may stop patients who are undergoing chemotherapy from losing their hair."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  New diagnosis of breast cancer stage 1-2\n\n          -  Planning to undergo neoadjuvant or adjuvant chemotherapy with curative intent\n\n          -  Chemotherapy must be planned for at least 4 cycles of full-dose anthracycline or\n             taxane based chemotherapy regimen,\n\n          -  Defined as one of the following regimens: - Adriamycin 60mg/m2 with cyclophosphamide\n             600mg/m2 - Epirubicin 90-100mg/m2 with cyclophosphamide 600mg/m2 - Paclitaxel\n             80mg-90/m2 weekly (every three weeks constitute a cycle), or 175 mg/m2 every 2-3\n             weeks as a single agent - Docetaxel 100mg/m2 as a single agent - Docetaxel 75mg/m2\n             with cyclophosphamide 600mg/m2 - Docetaxel 75mg/m2 with carboplatin AUC of 6 and\n             trastuzumab at standard doses\n\n          -  Trastuzumab at standard doses is allowed in combination with taxane based\n             chemotherapy\n\n          -  Administration of chemotherapy on a dose dense schedule is allowed as clinically\n             indicated.\n\n        Exclusion Criteria:\n\n          -  Stage 3 or 4 breast cancer or any other concurrent malignancy including hematological\n             malignancies (i.e. leukemia or lymphoma)\n\n          -  Baseline alopecia (defined CTCAE v4.0 grade > 0, see appendix B for CTCAE v4.0 scale)\n\n          -  Subjects with cold agglutinin disease or cold urticaria\n\n          -  Subjects who are scheduled for bone marrow ablation chemotherapy\n\n          -  Subjects receiving chemotherapy with concurrent anthracycline and taxane (AT or TAC)\n\n          -  Male gender"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "235", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986140", 
            "org_study_id": "H: 33692 SCALP"
        }, 
        "intervention": [
            {
                "arm_group_label": "Scalp Cooling", 
                "description": "Treatment with Orbis scalp cooling cap", 
                "intervention_name": "PAXMAN Orbis Scalp Cooler", 
                "intervention_type": "Device", 
                "other_name": "PAXMAN Orbis Scalp Cooler"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "No treatment to prevent hair loss", 
                "intervention_name": "Control No treatment to prevent hair loss", 
                "intervention_type": "Other", 
                "other_name": "No intervention"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast Cancer", 
            "Alopecia", 
            "Scalp", 
            "Cooling"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mmackenzie@hoannj.com", 
                    "last_name": "Michelle Mackenzie", 
                    "phone": "973-538-3593", 
                    "phone_ext": "2338"
                }, 
                "contact_backup": {
                    "email": "kfritsch@hoannj.com", 
                    "last_name": "Karen Fritsch", 
                    "phone": "973-538-3593"
                }, 
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Hematology & Oncology Associates of Northern New Jersey"
                }, 
                "investigator": {
                    "last_name": "Steven Papish, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lori.andrews@usoncology.com", 
                    "last_name": "Laurel Andrews", 
                    "phone": "214-370-1000"
                }, 
                "contact_backup": {
                    "email": "francis.collins@usoncology.com", 
                    "last_name": "Francis Collins", 
                    "phone": "(214)370-1000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Texas Oncology-Baylor Charles A. Sammons Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Cyntiha Osborne, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Kristen.Otte@bcm.edu", 
                    "last_name": "Kristen Otte, BS", 
                    "phone": "713-798-1999"
                }, 
                "contact_backup": {
                    "email": "breusser@bcm.edu", 
                    "last_name": "Brenda Reusser, BA", 
                    "phone": "713-798-1929"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Lester and Sue Smith Breast Center at Baylor College of Medicie"
                }, 
                "investigator": [
                    {
                        "last_name": "Polly Niravath, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mothaffar Rimawi, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kent Osborne, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mari Rude, NP", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sao Jiralerspong, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amber.mendoza@usoncology.com", 
                    "last_name": "Amber Mendoza", 
                    "phone": "713-467-1722"
                }, 
                "contact_backup": {
                    "email": "jamie.renard@usoncology.com", 
                    "last_name": "Jamie Renard", 
                    "phone": "713-467-1722"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77024"
                    }, 
                    "name": "USOncology / Texas Oncology-Memorial City"
                }, 
                "investigator": {
                    "last_name": "Frankie Holmes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Scalp Cooling for Alopecia Prevention (SCALP)", 
        "other_outcome": {
            "description": "Improved quality of life as a result of reduced hair loss is a primary motivator for developing the Paxman Scalp Cooling device. Quality of life will be assessed at baseline and 2-3 weeks after each course of chemotherapy. Three widely used and validated scales will be used: the EORTC QLQ C-30, HADS and BIS. Subjects will be evaluated at multiple time points and data will be analyzed using descriptive methods with median and inter quartile rang to assess the effect of treatment group and alopecia status on functioning, quality of life and depression.", 
            "measure": "Improved Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "4 to 8 Months"
        }, 
        "overall_contact": {
            "email": "kristen.otte@bcm.edu", 
            "last_name": "Kristen Otte", 
            "phone": "713-798-1999"
        }, 
        "overall_contact_backup": {
            "email": "caforema@bcm.edu", 
            "last_name": "Claudette Foreman", 
            "phone": "713-798-7315"
        }, 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Julie Nangia, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint will be success in hair preservation, defined as CTCAE v 4 alopecia grade <2, and will be assessed by a healthcare professional who is blinded to study treatment.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "4 to 8 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A safety follow-up for safety data will be done yearly for 5 years looking at time to first recurrence of breast cancer, overall survival, site of first recurrence, and incidence of isolated scalp metastasis. This will be collected during routine clinical observation", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "source": "Baylor Breast Care Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor Breast Care Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}